| scholarly article | Q13442814 |
| P2093 | author name string | Virginia A Triant | |
| P2860 | cites work | HIV infection: an independent risk factor of peripheral arterial disease | Q82659465 |
| Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study | Q83749885 | ||
| Association Between HIV Infection, Antiretroviral Therapy, and Risk of Acute Myocardial Infarction: A Cohort and Nested Case–Control Study Using Québec's Public Health Insurance Database | Q83885197 | ||
| Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy | Q83985084 | ||
| The Biology of Atherosclerosis: General Paradigms and Distinct Pathogenic Mechanisms Among HIV-Infected Patients | Q26862601 | ||
| Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy | Q27008328 | ||
| HIV infection and the risk of acute myocardial infarction | Q27347231 | ||
| Inflammation, coagulation and cardiovascular disease in HIV-infected individuals | Q28483645 | ||
| Angiotensin Converting Enzyme Inhibitor and HMG-CoA Reductase Inhibitor as Adjunct Treatment for Persons with HIV Infection: A Feasibility Randomized Trial | Q28484460 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database | Q30609632 | ||
| Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? | Q33184007 | ||
| Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study | Q33521080 | ||
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study | Q33602915 | ||
| Serum albumin and short-term risk for mortality and cardiovascular disease among HIV-infected veterans | Q33631163 | ||
| Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. | Q33649753 | ||
| Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection | Q33907642 | ||
| Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data | Q33946279 | ||
| Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients | Q33963850 | ||
| A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis | Q34137496 | ||
| HIV Infection, Inflammation, Immunosenescence, and Aging | Q34150710 | ||
| Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort | Q34204026 | ||
| No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis | Q34296639 | ||
| Increasing incidence of ischemic stroke in patients with HIV infection | Q34555429 | ||
| Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System | Q34564981 | ||
| Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study | Q34612901 | ||
| Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review | Q34651525 | ||
| Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). | Q34762935 | ||
| High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial | Q34763977 | ||
| T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women | Q34764361 | ||
| The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C | Q35174850 | ||
| Efficacy of Cell Phone-Delivered Smoking Cessation Counseling for Persons Living With HIV/AIDS: 3-Month Outcomes | Q35624478 | ||
| Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population | Q35949949 | ||
| Sudden Cardiac Death in Patients With Human Immunodeficiency Virus Infection | Q35973838 | ||
| Cardiovascular risk and body-fat abnormalities in HIV-infected adults | Q36000980 | ||
| Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study | Q36084113 | ||
| CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV. | Q42267244 | ||
| Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. | Q42278643 | ||
| Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study | Q42282082 | ||
| Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk | Q42289011 | ||
| Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. | Q42957305 | ||
| Aspirin is indicated for primary prevention of cardiovascular events in HIV-infected patients | Q42963366 | ||
| Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study | Q42992133 | ||
| Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients | Q43159096 | ||
| Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells | Q43281341 | ||
| HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study | Q43836101 | ||
| Angiographic features and cardiovascular risk factors in human immunodeficiency virus-infected patients with first-time acute coronary syndrome | Q44082432 | ||
| Renal Impairment Is Associated With Coronary Heart Disease in HIV-Positive Men | Q44250284 | ||
| Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population | Q44503156 | ||
| A critical epidemiological review of cardiovascular disease risk in HIV-infected adults: the importance of the HIV-uninfected comparison group, confounding, and competing risks. | Q44532412 | ||
| Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection | Q44725232 | ||
| Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. | Q45178322 | ||
| Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America | Q45382453 | ||
| Comparison of in-hospital mortality from acute myocardial infarction in HIV sero-positive versus sero-negative individuals | Q46078135 | ||
| Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitors | Q47754842 | ||
| Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study | Q50553891 | ||
| HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals | Q56837760 | ||
| Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events | Q57180859 | ||
| Class of Antiretroviral Drugs and the Risk of Myocardial Infarction | Q57181081 | ||
| Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study | Q57300568 | ||
| Clinical presentation of acute coronary syndrome in HIV infected adults: A retrospective analysis of a prospectively collected cohort | Q57631509 | ||
| Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy | Q57709917 | ||
| Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial | Q58000817 | ||
| Cardiovascular Disease Risk Prediction Measures | Q58375390 | ||
| Inflammation, Immune Activation, and CVD Risk in Individuals With HIV Infection | Q58375394 | ||
| Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the | Q58375437 | ||
| Coronary heart disease in HIV-infected individuals | Q73687564 | ||
| Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort | Q82657366 | ||
| Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection | Q36115626 | ||
| Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women | Q36154044 | ||
| Pentoxifylline Reduces Tumor Necrosis Factor-α and HIV-Induced Vascular Endothelial Activation | Q36250376 | ||
| Balancing Immunological Benefits and Cardiovascular Risks of Antiretroviral Therapy: When Is Immediate Treatment Optimal? | Q36338387 | ||
| A Randomized Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection | Q36346646 | ||
| Carotid Intima‐Media Thickness Progression in HIV‐Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation | Q36366360 | ||
| Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients | Q36379615 | ||
| HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation | Q36383621 | ||
| Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome | Q36440077 | ||
| Provider Compliance With Guidelines for Management of Cardiovascular Risk in HIV-Infected Patients | Q36567732 | ||
| Interventions to Address Chronic Disease and HIV: Strategies to Promote Smoking Cessation Among HIV-infected Individuals | Q36594551 | ||
| Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. | Q36807389 | ||
| Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers | Q36862952 | ||
| Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection | Q36875816 | ||
| Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons | Q36892885 | ||
| Comparison of Ischemic Stroke Incidence in HIV-Infected and Non–HIV-Infected Patients in a US Health Care System | Q36894824 | ||
| Risk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart Disease | Q36942884 | ||
| Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³. | Q37025746 | ||
| Arterial inflammation in patients with HIV. | Q37046942 | ||
| Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men | Q37086410 | ||
| Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study | Q37130166 | ||
| Non-calcified coronary plaque volume inversely related to CD4(+) T-cell count in HIV infection | Q37182926 | ||
| Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis | Q37215251 | ||
| Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial | Q37289596 | ||
| Association of C-reactive protein and HIV infection with acute myocardial infarction | Q37390630 | ||
| Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease | Q37390635 | ||
| The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease | Q37436594 | ||
| Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial | Q37504465 | ||
| Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta‐analysis | Q37993138 | ||
| HIV and Inflammation: Mechanisms and Consequences | Q38005046 | ||
| Smoking and HIV: Prevalence, Health Risks, and Cessation Strategies | Q38012348 | ||
| HIV-Specific Immune Dysregulation and Atherosclerosis | Q38013681 | ||
| Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians | Q38434908 | ||
| P433 | issue | 3 | |
| P921 | main subject | HIV | Q15787 |
| cardiovascular disease | Q389735 | ||
| P304 | page(s) | 199-206 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | Current HIV/AIDS reports | Q26842190 |
| P1476 | title | Cardiovascular disease and HIV infection | |
| P478 | volume | 10 |
| Q92171913 | A Framework for Using eHealth Interventions to Overcome Medical Mistrust Among Sexual Minority Men of Color Living with Chronic Conditions |
| Q55001110 | Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials. |
| Q34057868 | Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults |
| Q92341034 | Association of predicted 10 years cardiovascular mortality risk with duration of HIV infection and antiretroviral therapy among HIV-infected individuals in Durban, South Africa |
| Q38811225 | Astrocyte Elevated Gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND. |
| Q51779710 | Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection |
| Q34342368 | Chronic HIV disease and activation of the coagulation system |
| Q92626789 | Comorbidities in a sample of adults with HIV in Puerto Rico: an exploratory study |
| Q46950679 | Genome-wide admixture and association study of subclinical atherosclerosis in the Women's Interagency HIV Study (WIHS). |
| Q101454111 | HIV, Vascular Risk Factors, and Cognition in the Combination Antiretroviral Therapy Era: A Systematic Review and Meta-Analysis |
| Q60957273 | Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals |
| Q92582866 | Implementation Research Methodologies for Achieving Scientific Equity and Health Equity |
| Q64092710 | Increased incidences of noninfectious comorbidities among aging populations living with human immunodeficiency virus in Ecuador: a multicenter retrospective analysis |
| Q90012235 | Knowledge about modifiable risk factors for non-communicable diseases adults living with HIV in Rwanda |
| Q28392474 | Late-Onset Asthma Predicts Cardiovascular Disease Events: The Wisconsin Sleep Cohort |
| Q33828507 | Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers |
| Q59137576 | Metabolic and Cardiovascular Comorbidities Among Clinically Stable HIV Patients on Long-Term ARV Therapy in Five Ambulatory Clinics in Lima-Callao, Peru |
| Q64115522 | Molecular Imaging of Vascular Calcification with F-Sodium-Fluoride in Patients Infected with Human Immunodeficiency Virus |
| Q55017133 | Non-ST Elevation Myocardial Infarction and Severe Peripheral Artery Disease in a 20-Year-Old with Perinatally Acquired Human Immunodeficiency Virus Infection. |
| Q30235024 | Recent Insights into the HIV/AIDS Pandemic |
| Q50050405 | Role of Noncommunicable Diseases (NCDs) in Resource-Limited Settings (RLS). |
| Q37051131 | STD Clinic Patients' Awareness of Non-AIDS Complications of HIV Infection |
| Q37095598 | Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in Tanzania |
| Q55491369 | Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. |
| Q40163111 | Subclinical myocardial disease by cardiac magnetic resonance imaging and spectroscopy in healthy HIV/Hepatitis C virus-coinfected persons |
| Q91935402 | TNF-α-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging |
| Q61798413 | The association of mannose binding lectin genotype and immune response to Chlamydia pneumoniae: The Strong Heart Study |
| Q40519915 | Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder |
| Q49722994 | Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach |
Search more.